Literature DB >> 23325142

Redirection of T cells with a first fully humanized bispecific CD33-CD3 antibody efficiently eliminates AML blasts without harming hematopoietic stem cells.

C Arndt, M von Bonin, M Cartellieri, A Feldmann, S Koristka, I Michalk, S Stamova, M Bornhäuser, M Schmitz, G Ehninger, M Bachmann.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23325142     DOI： 10.1038/leu.2013.18

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  39 in total

1.  Expression of inhibitory receptors on intratumoral T cells modulates the activity of a T cell-bispecific antibody targeting folate receptor.

Authors:  Jens Schreiner; Daniela S Thommen; Petra Herzig; Marina Bacac; Christian Klein; Andreas Roller; Anton Belousov; Victor Levitsky; Spasenija Savic; Wolfgang Moersig; Franziska Uhlenbrock; Viola A Heinzelmann-Schwarz; Pablo Umana; Pavel Pisa; M von Bergwelt-Baildon; Didier Lardinois; Philipp Müller; Vaios Karanikas; Alfred Zippelius
Journal:  Oncoimmunology       Date:  2015-06-24       Impact factor: 8.110

Review 2.  Therapeutic Targeting of Siglecs using Antibody- and Glycan-Based Approaches.

Authors:  Takashi Angata; Corwin M Nycholat; Matthew S Macauley
Journal:  Trends Pharmacol Sci       Date:  2015-10       Impact factor: 14.819

Review 3.  Update on antigen-specific immunotherapy of acute myeloid leukemia.

Authors:  Sarah A Buckley; Roland B Walter
Journal:  Curr Hematol Malig Rep       Date:  2015-06       Impact factor: 3.952

4.  Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia.

Authors:  Carol O'Hear; Hiroto Inaba; Stanley Pounds; Lei Shi; Gary Dahl; W Paul Bowman; Jeffrey W Taub; Ching-Hon Pui; Raul C Ribeiro; Elaine Coustan-Smith; Dario Campana; Jeffrey E Rubnitz
Journal:  Cancer       Date:  2013-09-04       Impact factor: 6.860

5.  Costimulation improves the killing capability of T cells redirected to tumor cells expressing low levels of CD33: description of a novel modular targeting system.

Authors:  C Arndt; A Feldmann; M von Bonin; M Cartellieri; E-M Ewen; S Koristka; I Michalk; S Stamova; N Berndt; A Gocht; M Bornhäuser; G Ehninger; M Schmitz; M Bachmann
Journal:  Leukemia       Date:  2013-08-20       Impact factor: 11.528

Review 6.  Antibody Based Therapies in Acute Leukemia.

Authors:  Nirali N Shah
Journal:  Curr Drug Targets       Date:  2017       Impact factor: 3.465

7.  CD99 is a therapeutic target on disease stem cells in myeloid malignancies.

Authors:  Stephen S Chung; William S Eng; Wenhuo Hu; Mona Khalaj; Francine E Garrett-Bakelman; Montreh Tavakkoli; Ross L Levine; Martin Carroll; Virginia M Klimek; Ari M Melnick; Christopher Y Park
Journal:  Sci Transl Med       Date:  2017-01-25       Impact factor: 17.956

8.  Characterization of a bispecific FLT3 X CD3 antibody in an improved, recombinant format for the treatment of leukemia.

Authors:  Michael Durben; Dominik Schmiedel; Martin Hofmann; Fabian Vogt; Tina Nübling; Elwira Pyz; Hans-Jörg Bühring; Hans-Georg Rammensee; Helmut R Salih; Ludger Große-Hovest; Gundram Jung
Journal:  Mol Ther       Date:  2015-01-12       Impact factor: 11.454

Review 9.  Bispecific Antibodies for the Treatment of Acute Myeloid Leukemia.

Authors:  Daniel G Guy; Geoffrey L Uy
Journal:  Curr Hematol Malig Rep       Date:  2018-12       Impact factor: 3.952

10.  Targeting human C-type lectin-like molecule-1 (CLL1) with a bispecific antibody for immunotherapy of acute myeloid leukemia.

Authors:  Hua Lu; Quan Zhou; Vishal Deshmukh; Hardeep Phull; Jennifer Ma; Virginie Tardif; Rahul R Naik; Claire Bouvard; Yong Zhang; Seihyun Choi; Brian R Lawson; Shoutian Zhu; Chan Hyuk Kim; Peter G Schultz
Journal:  Angew Chem Int Ed Engl       Date:  2014-07-23       Impact factor: 15.336
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.